Steve Meyers serves as Chief Commercial Officer at Ocular Therapeutix Inc., a biopharmaceutical company dedicated to developing innovative therapies for ocular diseases. In this role, he leads the commercial strategy, including marketing, sales, and market access efforts for the company's pipeline, with a focus on advancing products like DEXTENZA and AXPAXLI to maximize patient reach and revenue growth. Meyers brings a wealth of expertise in ophthalmology, driving cross-functional teams to launch and commercialize therapies in a competitive landscape. With over 25 years in the pharmaceutical industry, Meyers has held senior leadership positions at leading companies such as Bausch + Lomb, where he was Vice President of U.S. Commercial Operations, overseeing a portfolio of ophthalmic products that generated billions in annual sales. Prior roles include executive positions at Allergan, where he spearheaded the successful launch of multiple blockbuster eye care drugs, and at Pfizer, contributing to market expansion strategies. His achievements include consistently exceeding sales targets, building high-performing teams, and navigating complex payer negotiations to improve access for underserved patients. Meyers' strategic vision has been instrumental in Ocular Therapeutix's commercial evolution, particularly as the company prepares for key product launches. A recognized leader in the field, he holds an MBA from the University of Southern California and a BS in Business Administration from California State University, Long Beach, and is a frequent speaker at industry conferences on ophthalmic commercialization trends.